FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154267675> ?p ?o ?g. }

• W2154267675 endingPage "S13" @default.
• W2154267675 startingPage "S13" @default.
• W2154267675 abstract "OBJECTIVE: To determine the impact of treatment on a disease-specific measure and to evaluate long-term safety and tolerability of a novel, oral tranexamic acid formulation (TA, Lysteda™) in women with heavy menstrual bleeding (HMB).DESIGN: After a screening menstrual cycle, women (aged 18–49 years) with cyclic HMB received TA 3.9 g/day for up to 5 days per menstrual cycle during a maximum of 27 cycles in this multicenter, long-term, open-label study.MATERIALS AND METHODS: The Aberdeen (Ruta) Menorrhagia Clinical Outcome Questionnaire (AMCOQ) was administered during a baseline cycle and after treatment cycles 1, 2, 3, 6, 9, 12, and 15. The 15-item questionnaire provides an overall global score estimating the effect of menorrhagia on patients' perceived health status. In part, it sums general information about the woman's period, types, amount of sanitary products used, and the impact of HMB on her physical, social, and general functions. Safety was assessed by adverse event (AE) monitoring, physical examinations, vital sign monitoring, laboratory testing, ophthalmologic examinations, and 12-lead electrocardiography. Efficacy and safety analyses were performed on the intent-to-treat (ITT) population (all randomized patients who received at least 1 dose of study drug).RESULTS: The ITT population included 723 women with treatment of 10,213 menstrual cycles. Significant improvements from baseline in the AMCOQ global scores were observed at all evaluated cycles (P<.0001). The reduction in AMCOQ scores suggests a consistent improvement in HMB-impacted activities, which were maintained from the 1st through 15th cycle. TA was generally well tolerated; the majority of AEs were mild to moderate in severity. The frequency of treatment-related gastrointestinal AEs was low and no thrombotic or thromboembolic AEs occurred.CONCLUSION: Long-term treatment with this new TA formulation was well tolerated and ensured immediate and enduring improvement in quality of life in women with HMB. OBJECTIVE: To determine the impact of treatment on a disease-specific measure and to evaluate long-term safety and tolerability of a novel, oral tranexamic acid formulation (TA, Lysteda™) in women with heavy menstrual bleeding (HMB). DESIGN: After a screening menstrual cycle, women (aged 18–49 years) with cyclic HMB received TA 3.9 g/day for up to 5 days per menstrual cycle during a maximum of 27 cycles in this multicenter, long-term, open-label study. MATERIALS AND METHODS: The Aberdeen (Ruta) Menorrhagia Clinical Outcome Questionnaire (AMCOQ) was administered during a baseline cycle and after treatment cycles 1, 2, 3, 6, 9, 12, and 15. The 15-item questionnaire provides an overall global score estimating the effect of menorrhagia on patients' perceived health status. In part, it sums general information about the woman's period, types, amount of sanitary products used, and the impact of HMB on her physical, social, and general functions. Safety was assessed by adverse event (AE) monitoring, physical examinations, vital sign monitoring, laboratory testing, ophthalmologic examinations, and 12-lead electrocardiography. Efficacy and safety analyses were performed on the intent-to-treat (ITT) population (all randomized patients who received at least 1 dose of study drug). RESULTS: The ITT population included 723 women with treatment of 10,213 menstrual cycles. Significant improvements from baseline in the AMCOQ global scores were observed at all evaluated cycles (P<.0001). The reduction in AMCOQ scores suggests a consistent improvement in HMB-impacted activities, which were maintained from the 1st through 15th cycle. TA was generally well tolerated; the majority of AEs were mild to moderate in severity. The frequency of treatment-related gastrointestinal AEs was low and no thrombotic or thromboembolic AEs occurred. CONCLUSION: Long-term treatment with this new TA formulation was well tolerated and ensured immediate and enduring improvement in quality of life in women with HMB." @default.
• W2154267675 created "2016-06-24" @default.
• W2154267675 creator A5001930283 @default.
• W2154267675 creator A5012496878 @default.
• W2154267675 creator A5040929763 @default.
• W2154267675 creator A5047836432 @default.
• W2154267675 creator A5064337082 @default.
• W2154267675 creator A5073917801 @default.
• W2154267675 date "2010-09-01" @default.
• W2154267675 modified "2023-09-27" @default.
• W2154267675 title "Long-term quality of life and safety of a new tranexamic acid menorrhagia treatment" @default.
• W2154267675 doi "https://doi.org/10.1016/j.fertnstert.2010.07.051" @default.
• W2154267675 hasPublicationYear "2010" @default.
• W2154267675 type Work @default.
• W2154267675 sameAs 2154267675 @default.
• W2154267675 citedByCount "1" @default.
• W2154267675 countsByYear W21542676752018 @default.
• W2154267675 crossrefType "journal-article" @default.
• W2154267675 hasAuthorship W2154267675A5001930283 @default.
• W2154267675 hasAuthorship W2154267675A5012496878 @default.
• W2154267675 hasAuthorship W2154267675A5040929763 @default.
• W2154267675 hasAuthorship W2154267675A5047836432 @default.
• W2154267675 hasAuthorship W2154267675A5064337082 @default.
• W2154267675 hasAuthorship W2154267675A5073917801 @default.
• W2154267675 hasBestOaLocation W21542676751 @default.
• W2154267675 hasConcept C126322002 @default.
• W2154267675 hasConcept C141071460 @default.
• W2154267675 hasConcept C159110408 @default.
• W2154267675 hasConcept C197934379 @default.
• W2154267675 hasConcept C2778375690 @default.
• W2154267675 hasConcept C2779058012 @default.
• W2154267675 hasConcept C2779637338 @default.
• W2154267675 hasConcept C2779951463 @default.
• W2154267675 hasConcept C2908647359 @default.
• W2154267675 hasConcept C2991743468 @default.
• W2154267675 hasConcept C71315377 @default.
• W2154267675 hasConcept C71924100 @default.
• W2154267675 hasConcept C99454951 @default.
• W2154267675 hasConceptScore W2154267675C126322002 @default.
• W2154267675 hasConceptScore W2154267675C141071460 @default.
• W2154267675 hasConceptScore W2154267675C159110408 @default.
• W2154267675 hasConceptScore W2154267675C197934379 @default.
• W2154267675 hasConceptScore W2154267675C2778375690 @default.
• W2154267675 hasConceptScore W2154267675C2779058012 @default.
• W2154267675 hasConceptScore W2154267675C2779637338 @default.
• W2154267675 hasConceptScore W2154267675C2779951463 @default.
• W2154267675 hasConceptScore W2154267675C2908647359 @default.
• W2154267675 hasConceptScore W2154267675C2991743468 @default.
• W2154267675 hasConceptScore W2154267675C71315377 @default.
• W2154267675 hasConceptScore W2154267675C71924100 @default.
• W2154267675 hasConceptScore W2154267675C99454951 @default.
• W2154267675 hasIssue "4" @default.
• W2154267675 hasLocation W21542676751 @default.
• W2154267675 hasOpenAccess W2154267675 @default.
• W2154267675 hasPrimaryLocation W21542676751 @default.
• W2154267675 hasRelatedWork W1966541007 @default.
• W2154267675 hasRelatedWork W1979403001 @default.
• W2154267675 hasRelatedWork W1982967451 @default.
• W2154267675 hasRelatedWork W2060217356 @default.
• W2154267675 hasRelatedWork W2120216515 @default.
• W2154267675 hasRelatedWork W2158763636 @default.
• W2154267675 hasRelatedWork W2163254251 @default.
• W2154267675 hasRelatedWork W2800022962 @default.
• W2154267675 hasRelatedWork W4366131861 @default.
• W2154267675 hasRelatedWork W2182522524 @default.
• W2154267675 hasVolume "94" @default.
• W2154267675 isParatext "false" @default.
• W2154267675 isRetracted "false" @default.
• W2154267675 magId "2154267675" @default.
• W2154267675 workType "article" @default.